EMD-67994

Single-particle
2.43 Å
EMD-67994
3D View Gallery
Deposition: 24/12/2025
Map released: 29/04/2026
Last modified: 29/04/2026
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-67994

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-21tw summary report (pdf.gz) Map-21tw FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

TNF-alpha in complex with the TNF-alpha inhibitor Ozoralizumab (OZR)

EMD-67994

Single-particle
2.43 Å
EMD-67994
3D View Gallery
Deposition: 24/12/2025
Map released: 29/04/2026
Last modified: 29/04/2026
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens
Sample: TNF-alpha in complex with the TNF-alpha inhibitor Ozoralizumab (OZR)
Fitted models: 21tw

Deposition Authors: Tanaka Y, Sato K, Mima M, Mishima-Tsumagari C
Cryo-EM elucidates the interaction mechanism of ozoralizumab, a humanized anti-TNF alpha NANOBODY® compound.
Mima M, Sato K, Yokoyama T, Mishima-Tsumagari C, Ohnuki T, Tanaka Y, Iwamoto K
(2026) Biochem Biophys Res Commun , 816 , 153572 - 153572
PUBMED: 41935434
DOI: doi:10.1016/j.bbrc.2026.153572
ISSN: 1090-2104
ASTM: BBRCA9
Grant Support: